Page last updated: 2024-08-24

azelnidipine and Arterial Obstructive Diseases

azelnidipine has been researched along with Arterial Obstructive Diseases in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cui, TX; Horiuchi, M; Iwai, M; Jinno, T; Li, JM; Li, Z; Liu, HW; Ogihara, T; Rakugi, H	1

Other Studies

1 other study(ies) available for azelnidipine and Arterial Obstructive Diseases

Article	Year
Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Occlusive Diseases; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cell Division; Dihydropyridines; Drug Synergism; Drug Therapy, Combination; Imidazoles; Inflammation; Male; MAP Kinase Signaling System; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Olmesartan Medoxomil; Oxidative Stress; Receptor, Angiotensin, Type 1; Tetrazoles; Tunica Intima	2004

Article

Year

Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.

Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:2

Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Occlusive Diseases; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cell Division; Dihydropyridines; Drug Synergism; Drug Therapy, Combination; Imidazoles; Inflammation; Male; MAP Kinase Signaling System; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Olmesartan Medoxomil; Oxidative Stress; Receptor, Angiotensin, Type 1; Tetrazoles; Tunica Intima

2004